Drugs and Devices

FDA drug approvals

On Jan. 28, the Food and Drug Administration (FDA) approved:

  • Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Read more.
  • Halaven (eribulin mesylate) for the treatment of liposarcoma that is unresectable or metastatic. Treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. Read more.



Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares